Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 1999

View Archived Issues

Final analysis presented for phase II Altropane diagnosis trial

Celsion signs option agreement for cancer therapy technology

Data on adefovir dipivoxil against HBV presented at EASL conference

News from AACR: chemopreventive properties of NSAIDs, including COX-2 inhibitors

U.K approval of Atrix's periodontal drug delayed

Inhibitex signs research agreement with BioResearch Ireland

U.K. team develops novel male contraceptive methodology

Pivotal studies of anti-HIV drug candidate under way on three continents

Preclinical and clinical results support efficacy of Trovert in treatment of acromegaly

New series of osteogenesis-promoting agents developed at Taisho

Differentiation-inducing vitamin D derivatives described by Teikoku Hormone

Compounds and methods for treating or diagnosing leishmaniasis disclosed by Corixa

Takeda presents new tachykinin antagonists

Pharmacokinetics and MTD of BBR-2778 determined in cancer patients

Estrogen/antiandrogenic progesterone combination for hirsutism: efficacy of long-term Rx

In vitro and in vivo profile of AG-7352 described in further detail at AACR meeting

Korean researchers report preclinical toxicity and pharmacokinetics of CKD-602 continuous infusion

Presence of GHRH receptor is essential for response to treatment with GHRPs

U.K. launch announced for anticonvulsant prodrug

EntreMed paves the way for clinical evaluation of recombinant human Endostatin

Vion presents parent and prodrug ribonucleotide reductase inhibitors at AACR

Jenapharm's scavestrogen is more potent than estrogen in preventing atherosclerosis

New taxane analogue shows potential as an orally active alternative to paclitaxel

Canadian approval obtained, launch imminent for Celebrex

Low-dose IL-2 provides benefits in treatment-refractory HCV patients

Two gene therapy approaches shown effective in treating hepatocellular carcinoma in rats

Merger of Nippon Glaxo and Nippon Wellcome

Good tolerance and in vivo proteasome inhibition demonstrated for multiple doses of PS-341

Phytopharm opens new facility for manufacture of antiobesity drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...